In this study, we describe a novel approach to achieve replicative selectivity of conditionally replicative adenovirus that is based upon trans-splicing ribozyme-mediated replacement of cancer-specific RNAs. We developed a specific ribozyme that can reprogram human telomerase reverse transcriptase (hTERT) RNA to induce adenoviral E1A gene expression selectively in cancer cells that express the RNA. Western blot analysis showed that the ribozyme highly selectively triggered E1A expression in hTERT-expressing cancer cells. RT-PCR and sequencing analysis indicated that the ribozyme-mediated E1A induction was caused via a high fidelity trans-splicing reaction with the targeted residue in the hTERTexpressing cells. Moreover, reporter activity under the control of an E1A-dependent E3 promoter was highly transactivated in hTERT-expressing cancer cells. Therefore, adenovirus containing the hTERT RNA-targeting transsplicing ribozyme would be a promising anticancer agent through selective replication in cancer cells and thus specific destruction of the infected cells.
Cancer remains one of the top causes of death in humans. A number of strategies including surgery, radiation, and chemotherapeutic approaches have been used for cancer treatment; however, most of them are accompanied by significant side effects and the lack of controlled trials [6] . Use of replicative viral reagents represents a new approach to the neoplastic disease. Targeted tumor cell killing by the viral agent is achieved by direct consequence of the viral replication. Several conditionally oncolytic viruses that selectively infect or replicate in cancer cells, but leave normal cells, have been identified. Some are naturally attenuated viral strains that more effectively infect or replicate in cancer cells. Others are genetically modified to mediate cytotoxicity from the oncolytic effects [1, 4, 10] . However, this antitumor agent is largely limited to specific gene-deficient tumors and frequently harbors low in vivo efficacy. Additionally, tissue-specific promoters used in these viral vectors caused limitations in their antitumor spectra to specific cancer types [11] .
Tetrahymena group I intron could target and cleave a substrate RNA and trans-splice an exon attached at its 3' end onto the cleaved target RNA in mammalian cells as well as in bacteria. The trans-splicing ribozyme has been developed to revise mutant transcripts associated with several human genetic and malignant diseases [13, 14, 16] . Moreover, we demonstrated that the ribozyme could selectively induce antiviral gene activities in HCV RNAcontaining cells through the specific RNA replacement of the HCV RNA [15] . Furthermore, we have recently shown that the ribozymes could replace cancer-specific transcripts such as human telomerase reverse transcriptase (hTERT) RNA or cytoskeleton-associated protein 2 transcript with RNA exerting cytotoxic activity, and thus the ribozymes could specifically regress cancer cells expressing the target RNA [2, 7, 9, 12, 17] . This RNA replacement approach would be a more attractive approach for cancer therapy because it should inhibit or reduce the expression of the target RNA and simultaneously produce therapeutic gene activity selectively in the target RNA-associated cancer cells.
In this study, we propose a new conditionally oncolytic adenovirus whose selective replication in cancers can be regulated at the post-transcriptional level. To this end, we constructed a hTERT-targeting trans-splicing ribozyme harboring the adenoviral E1A gene that stimulates S-phase entry and transactivates both viral and cellular genes that are critical for a productive viral infection [3] . We investigated whether the specific ribozyme can induce expression of the E1A gene, effectively and selectively, in hTERT-expressing cancer cells through the targeted RNA replacement. Moreover, we verified the selective trans-activity of E1A protein by the ribozyme in the target RNA-expressing cells.
MATERIAL AND METHODS
Construction of Trans-Splicing Ribozyme Expression vectors encoding for hTERT-specific trans-splicing ribozymes under the control of the cytomegalovirus (CMV) promoter were constructed as previously described [12] . Briefly, the Rib21AS ribozyme targeting U21 on the hTERT RNA was generated to harbor the extended internal guide sequence, which includes as an extension of the P1 helix, an additional 6-nt-long P10 helix, and a 325-nt-long antisense sequence complementary to the downstream region of the targeted hTERT RNA uridine. The cDNA as a 3' exon encoding for the adenoviral E1A open reading frame gene (orf) or adenoviral 5'UTR plus orf gene was inserted into the NruI/BamHI site downstream of the modified group I intron expression construct, and designated pCMV-Rib21AS-E1A and pCMV-Rib21AS-UTR-E1A, respectively. The pCMV-E1A and pCMV-UTR-E1A vectors encoding the E1A orf and 5'UTR plus E1A orf controlled by the CMV promoter, respectively, were generated as controls.
Cell Culture SK-OV3 (human ovarian cancer cell line), MCF7 (human breast cancer cell line), HeLa (human cervical cancer cell line), HCT116 (human colorectal cancer cell line), Hep3B (human hepatocarcinoma cell line), AGS (human gastric cancer cell line), HT-29 (human colorectal cancer cell line), IMR90 (telomerase-negative normal human lung fibroblast), SK-Lu1 (telomerase-negative human lung adenocarcinoma), and THLE3 (SV40 large T antigen immortalized but nontumorigenic normal liver cells) were purchased from ATCC (Manassas, VA, USA). The SK-OV3, HeLa, HCT116, AGS, and HT-29 cells were maintained in DMEM supplemented with 10% heat-inactivated FBS (Jeil Biotech Services Inc., Daegu, Korea). The Hep3B, SK-Lu1, and IMR90 cells were cultured in EMEM with 10% FBS. MCF7 cells were grown in RPMI 1640 with 10% FBS. The THLE3 cells were cultured in bronchial/tracheal epithelial cell growth medium (Cambrex, East Rutherford, NJ, USA) with 10% FBS, 6.5 ng triiodothyromine/ml, 50 µg gentamycin/ml, and 50 ng amphotericin-B/ml. The transfection reagent for each cell was as follows: SK-OV3, MCF7, Hep3B, AGS, HT-29, IMR90, and THLE3 cells, ExGen 500 (Fermentas, Hanover, MD, USA); HeLa, HCT116, Lipofectamine (Invitrogen, Carlsbad, CA, USA); SK-Lu1, DMRIE-C (Invitrogen).
Western Blot Analysis
Cells were washed in PBS, scraped in 100 µl of lysis buffer (HEPES 50 mM, NaCl 150 mM, PMSF 0.1 mM, NaVanadate 1.0 mM, Triton X-100 1.0%, glycerol 10.0%, pH 7.4) and solubilized for 60 min at 4 o C and centrifuged for fractionation. Total protein was quantitated using a Bio-Rad DC assay kit (Bio-Rad, Hercules, CA, USA), resolved by 10% SDS-PAGE, and then transferred to a polyvinylidene difluoride membrane (Millipore, Bedford, MA, USA). The membrane was blocked in 5% non-fat milk in PBS containing 0.1% Tween-20 for 1 h at room temperature and probed with antibodies specific to E1A (Santa Cruz Biotechnology, Santa Cruz, CA, USA) or actin (Santa Cruz Biotechnology). Subsequently, the membrane was incubated with HRP-conjugated secondary antibody for 1 h at room temperature. Finally, the membrane was developed by the enhanced chemiluminescence detection method (Amersham Phamacia, Cardiff, UK).
RT-PCR Analysis
For the analysis of trans-splicing products in cells, total RNA was isolated from ribozyme vector-transfected cells 24 h after transfection with guanidine isothiocyanate supplemented with 20 mM EDTA. RNA (5 µg) was reverse transcribed with an oligo(dT) primer in the presence of 10 mM L-argininamide, and the resulting cDNA was amplified with a 5' primer specific for the hTERT RNA (5'-GGG GAATTCAGCGCTGCGTCCTGCT-3') and with a 3' primer specific for the 3' exon E1A sequence (5'-CCCAAGCTTTCGTCACTGG GTGGAAAGCC-3'). The amplified cDNA was then reamplified with a 5' primer specific for the hTERT RNA and with a nested 3' primer specific for the E1A sequence (5'-CCCAAGCTTCCGGTAC AAGGTTTGGCAT-3'). The amplified cDNA was then cloned and sequenced. For the internal control, cDNAs were amplified with GAPDH primers (5'-TGACATCAAGAAGGTGGTGA-3' and 5'-TCCACCACCCTGTTGCTGTA-3').
Luciferase Assay
The reporter gene construct encoding firefly luciferase under the E1A-dependent E3 promoter was transiently co-transfected with pCMV-Rib21AS-E1A or pCMV-E1A along with phRL-TK (Promega, Madison, WI, USA), which encodes Renilla luciferase under the TK promoter and is used for normalization of transfection efficiency. Twenty-four hours after transfection, cells were lysed and luciferase activity was determined by chemiluminescence in a FB12 Luminometer (Berthold Detection System, Oak Ridge, TN, USA) using the dualluciferase reporter assay system (Promega).
RESULTS

Design of Adenoviral E1A Gene Expressing TransSplicing Ribozyme
We modified a ribozyme (designated Rib21AS), which was directed at U21 on the hTERT RNA, to contain an extension of the P1 helix, a 6-nt-long addition of the P10 helix, and a 325-nt-long antisense sequence that was complementary to the downstream region of the targeted uridine of the hTERT RNA. This modification enhanced the specificity and efficacy of group I-based trans-splicing ribozyme activity in cells [12] . A set of ribozymes were constructed to harbor adenoviral E1A orf with or without 5'UTR as 3' exon ( Fig. 1) .
Selective Induction of E1A Gene Expression in hTERTPositive Cell Lines by the Specific Ribozyme
To observe whether the modified ribozymes could react with and trans-splice the endogenous hTERT RNA and thus induce the expression of E1A proteins selectively in hTERT(+) cells, we transfected expression vectors encoding the specific ribozymes into variant hTERT-positive or -negative cells and assessed and compared the quantity of E1A production in the cells (Fig. 2) . E1A proteins were efficiently produced through the transfection of ribozyme expression vector pCMV-Rib21AS-E1A or pCMV-Rib21AS-UTR-E1A (Fig. 2A, lanes 4 or 5, respectively, and Fig. 2C ) in hTERT(+) cells. Inclusion of 5'UTR in the 3' exon of the ribozyme improved the E1A production. Neither transfection of the control vector nor pCMV-Rib21AS-Fluc, however, produced any E1A proteins in the cells (Fig. 2A, lanes 2  and 3) . Noticeably, little E1A proteins could be produced with the transfection of the ribozyme expression vectors in hTERT(-) cells (Fig. 2B, lanes 4 and 5, and Fig. 2C ).
Trans-Splicing Reaction in hTERT-Positive Cancer Cells by the Specific Ribozyme
We determined whether the ribozyme-mediated selective E1A expression in hTERT(+) cancer cells is due to a specific and high-fidelity trans-splicing reaction with hTERT RNA in those cells. Ribozyme transfection generated trans-spliced products in hTERT(+) AGS cells (Fig. 3A,  lanes 3 and 4) but not in an RNA sample isolated from mock-transfected AGS cells mixed with ribozyme-transfected SK-Lu 1 cells which are hTERT(-) (Fig. 3A, lanes 5 and  6) . This result indicates that the amplified product observed in the ribozyme-transfected cells was generated through the trans-splicing reaction specifically inside the hTERT(+) cells, but neither during RNA manipulation nor via nonspecific reaction. Sequence analyses of the transspliced products verified that the ribozyme accurately targeted U21 of the hTERT RNA and spliced its 3' exon into the target RNA in the cells (Fig. 3B and 3C ).
Selective Induction of E3 Promoter-Controlled Reporter Expression in hTERT-Positive Cell Lines by the Specific Ribozyme
The E1A gene inserted into the 3' exon of the ribozyme contains the full E1A gene sequence. Therefore, the transspliced E1A protein provided by the ribozyme should be functional selectively in hTERT(+) cells. In order to verify the function of produced E1A in cells, we monitored the level of firefly luciferase expression under the control of the adenoviral E3 promoter whose activity is induced by the adenoviral E1A protein (Fig. 4A) [8] . Transfection of the ribozyme expression vector efficiently induced firefly luciferase activity in all of tested hTERT(+) cancer cells, the level of which is comparable to the level in cells transfected with control pCMV-E1A vector (Fig. 4B) . In sharp contrast, the specific ribozyme negligibly induced reporter gene activity in hTERT(-) cells when compared with vector control. These results suggest that the specific trans-splicing ribozyme selectively produced functional E1A protein in hTERT(+) cancer cells.
DISCUSSION
In this study, we developed a hTERT-targeting transsplicing ribozyme, which can selectively induce adenoviral E1A gene expression in hTERT(+) cancer cells. The E1A expression occurred mainly through RNA replacement via highly specific trans-splicing reaction with the targeted hTERT RNA in the cells. Importantly, induction of the adenoviral E1A gene by the ribozyme activated E1A-dependent E3 promoter activity selectively in hTERT(+) cancer cells with efficiency comparable to that associated with the strong CMV promoter-derived E1A gene expression.
Cancer-specific expression of adenoviral E1A with tumor-or tissue-specific promoters has been proposed as a scheme to engineer conditionally oncolytic adenovirus [11] . However, the above approach could be limited owing to leaky specificity of the specific promoters when inserted into the viral genome [18] . Recently, posttranscriptional control of the adenoviral E1A expression by using normal tissue-specific microRNA was proposed as an alternate specific and safer virotherapy strategy against cancer [5] . However, we could not completely exclude the possibility of cytotoxicity in normal cells due to sequestering of the normal microRNA pathway. Moreover, systems using specific promoter or microRNA control would be useful only in specific tumor types. In contrast, regulation of E1A expression via the trans-splicing ribozyme system will be safer, because it occurs through exogenously introduced catalytic activity of the ribozyme, but not inherent cellular machinery. Additionally, the ribozyme could be a more potent anticancer tool because of its ability of specific induction of E1A activity combined with the capability of target inhibition. Noticeably, telomerase activity is highly elevated in most cancers. Therefore, the adenovirus equipped with the hTERT-specific ribozyme developed here will be useful as a conditionally replicative oncolytic virus with high efficacy and safety for diverse cancer types.
